AMGEN INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 309 USD | +10.99% |
|
+15.32% | +8.10% |
| 09:16pm | News Highlights : Top Company News of the Day - Friday at 3 PM ET | DJ |
| 08:36pm | Equities Climb Intraday Amid Apple Rally as Traders Parse Jobs Data | MT |
Financials (USD)
| Sales 2024 * | 33.01B | Sales 2025 * | 34.07B | Capitalization | 149B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.27B | Net income 2025 * | 6.96B | EV / Sales 2024 * | 5.92 x |
| Net Debt 2024 * | 46.28B | Net Debt 2025 * | 40.27B | EV / Sales 2025 * | 5.55 x |
| P/E ratio 2024 * |
23.6
x | P/E ratio 2025 * |
18.5
x | Employees | 26,700 |
| Yield 2024 * |
3.33% | Yield 2025 * |
3.6% | Free-Float | 99.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amgen Inc.
More recommendations
More press releases
More news
| 1 day | +10.99% | ||
| 1 week | +15.32% | ||
| Current month | +13.66% | ||
| 1 month | +13.46% | ||
| 3 months | -3.30% | ||
| 6 months | +15.37% | ||
| Current year | +8.10% |
1 week
268.99
322.54
1 month
260.68322.54
Current year
260.68329.72
1 year
211.71329.72
3 years
198.64329.72
5 years
166.30329.72
10 years
109.41329.72
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 06-05-31 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 19-10-22 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | Dec. 17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 17-02-02 |
Ellen Kullman
BRD | Director/Board Member | 68 | 16-10-13 |
Robert Williams
BRD | Director/Board Member | 75 | 14-10-16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 120 M€ | +11.38% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 311.1 | +11.76% | 8 697 237 |
| 24-05-02 | 278.4 | +0.37% | 3,177,473 |
| 24-05-01 | 277.4 | +1.25% | 2,323,935 |
| 24-04-30 | 273.9 | -0.88% | 2,477,347 |
| 24-04-29 | 276.4 | +2.37% | 2,678,969 |
Delayed Quote Nasdaq, May 03, 2024 at 03:56 pm EDT
More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
278.4
USD
Average target price
304.4
USD
Spread / Average Target
+9.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.10% | 149B | |
| +26.51% | 681B | |
| +21.85% | 556B | |
| -4.75% | 361B | |
| +16.99% | 325B | |
| +5.74% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -3.40% | 157B |
- Stock Market
- Equities
- AMGN Stock
